During the last session, Omega Therapeutics Inc (NASDAQ:OMGA)’s traded shares were 13.42 million, with the beta value of the company hitting 1.67. At the end of the trading day, the stock’s price was $0.22, reflecting an intraday loss of -15.19% or -$0.04. The 52-week high for the OMGA share is $4.46, that puts it down -1927.27 from that peak though still a striking 54.55% gain since the share price plummeted to a 52-week low of $0.10. The company’s market capitalization is $12.21M, and the average trade volume was 7.85 million shares over the past three months.
Omega Therapeutics Inc (OMGA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. OMGA has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.28.
Omega Therapeutics Inc (NASDAQ:OMGA) trade information
Omega Therapeutics Inc (OMGA) registered a -15.19% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -15.19% in intraday trading to $0.22, hitting a weekly high. The stock’s 5-day price performance is 76.54%, and it has moved by -63.07% in 30 days. Based on these gigs, the overall price performance for the year is -94.57%.
The consensus price target of analysts on Wall Street is $9, which implies an increase of 97.56% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $11 respectively. As a result, OMGA is trading at a discount of -4900.0% off the target high and -3081.82% off the low.
Omega Therapeutics Inc (OMGA) estimates and forecasts
In the rating firms’ projections, revenue will increase 100.29% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 825k as predicted by 2 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 850k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 989k and 2.36M respectively. In this case, analysts expect current quarter sales to shrink by -16.58% and then drop by -63.98% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -48.08%. While earnings are projected to return -26.67% in 2025.
OMGA Dividends
Omega Therapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 6.24 million shares, is of FMR LLC’s that is approximately 11.3181% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $12.92 million.
